AU2008254989B2 - Hypercompressed particles for controlled release of ophthalmic medications - Google Patents

Hypercompressed particles for controlled release of ophthalmic medications Download PDF

Info

Publication number
AU2008254989B2
AU2008254989B2 AU2008254989A AU2008254989A AU2008254989B2 AU 2008254989 B2 AU2008254989 B2 AU 2008254989B2 AU 2008254989 A AU2008254989 A AU 2008254989A AU 2008254989 A AU2008254989 A AU 2008254989A AU 2008254989 B2 AU2008254989 B2 AU 2008254989B2
Authority
AU
Australia
Prior art keywords
ophthalmic
poly
polymer
lactide
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008254989A
Other languages
English (en)
Other versions
AU2008254989A1 (en
Inventor
Weiliam Chen
Barry Libin
Jeffrey M. Liebmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUSTAINED NANO SYSTEMS LLC
Original Assignee
SUSTAINED NANO SYSTEMS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUSTAINED NANO SYSTEMS LLC filed Critical SUSTAINED NANO SYSTEMS LLC
Publication of AU2008254989A1 publication Critical patent/AU2008254989A1/en
Application granted granted Critical
Publication of AU2008254989B2 publication Critical patent/AU2008254989B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008254989A 2007-05-14 2008-05-14 Hypercompressed particles for controlled release of ophthalmic medications Ceased AU2008254989B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93010507P 2007-05-14 2007-05-14
US60/930,105 2007-05-14
PCT/US2008/006195 WO2008143906A2 (en) 2007-05-14 2008-05-14 Hypercompressed particles for controlled release of ophthalmic medications

Publications (2)

Publication Number Publication Date
AU2008254989A1 AU2008254989A1 (en) 2008-11-27
AU2008254989B2 true AU2008254989B2 (en) 2013-06-06

Family

ID=40072625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008254989A Ceased AU2008254989B2 (en) 2007-05-14 2008-05-14 Hypercompressed particles for controlled release of ophthalmic medications

Country Status (6)

Country Link
US (1) US20080292680A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2160184B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2008254989B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2704111C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN266731B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2008143906A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
WO2008150867A2 (en) 2007-05-29 2008-12-11 Innova Materials, Llc Surfaces having particles and related methods
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
EP2421517A4 (en) * 2009-04-23 2013-08-07 Sustained Nano Systems Llc DONATION DEVICE WITH CONTROLLED OUTPUT
PL2493459T3 (pl) * 2009-10-30 2017-06-30 Aton Pharma Inc Urządzenia do doocznego podawania leku
EP3651771B1 (en) * 2017-07-11 2023-08-30 Sustained Nano Systems LLC Radiation sterilization of hypercompressed polymer dosage forms
BR112020000506A2 (pt) 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
CN112354071B (zh) * 2020-11-06 2022-11-29 淄博市中心医院 一种泌尿外临床前列腺扩张装置
CN112472244B (zh) * 2020-12-12 2021-10-22 常州安康医疗器械有限公司 一种具有监视功能的球囊穿刺器

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2055522A1 (en) * 1990-12-12 1992-06-13 Masako Andoh Microspheres for ophthalmic use
US5725869A (en) * 1994-06-20 1998-03-10 Zeneca Limited Microsphere reservoirs for controlled release application
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
US6077534A (en) * 1997-09-02 2000-06-20 Klinge Pharma Gmbh Production of pharmaceutical formulations for treatment of edema and venous disorders
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
BR9908936A (pt) * 1998-03-20 2005-10-25 Takeda Chemical Industries Ltd Processos para produzir uma preparação de liberação sustentada, e para produzir um pó de polipeptìdeo fisiologicamente ativo, preparação de liberação sustentada, pó de polipeptìdeo fisiologicamente ativo, e, usos do pó polipeptìdeo fisiologicamente ativo, e de um solvente orgânico miscìvel em água e/ou um sal volátil
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
RU2253452C2 (ru) * 2000-10-30 2005-06-10 Эро-Селтик С.А. Композиции гидрокодона с контролируемым высвобождением
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
CA2548822C (en) * 2003-12-08 2015-08-11 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
EP1787643A1 (en) * 2004-09-09 2007-05-23 Jimenez Bayardo, Arturo Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof

Also Published As

Publication number Publication date
CA2704111C (en) 2017-06-20
AU2008254989A1 (en) 2008-11-27
CA2704111A1 (en) 2008-11-27
EP2160184A2 (en) 2010-03-10
WO2008143906A2 (en) 2008-11-27
IN266731B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-28
EP2160184B1 (en) 2018-03-07
US20080292680A1 (en) 2008-11-27
EP2160184A4 (en) 2013-08-07
WO2008143906A3 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
AU2008254989B2 (en) Hypercompressed particles for controlled release of ophthalmic medications
US20090148498A1 (en) Controlled release implantable dispensing device and method
US8071119B2 (en) Controlled release implantable dispensing device and method
KR101430760B1 (ko) 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
CA2700072C (en) Steroid containing drug delivery systems
RU2440102C2 (ru) Системы доставки лекарственного средства внутрь глаза
TW200538163A (en) Retinoid-containing sustained release intraocular drug delivery systems and related methods
MX2007003789A (es) Suministro ocular de formulaciones polimericas para suministro.
Deshpande et al. Bioerodible polymers for ocular drug delivery
JP6250005B2 (ja) 制御放出製剤
Guidetti et al. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers
US20100173000A1 (en) Controlled release implantable dispensing device and method

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired